LYRA THERAPEUTICS INC (LYRA)
OTCHealth CareBiotechnologySnapshot 2026-09-04
$0.200.00%
Close 2026-09-03 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LYRA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 0.4 | 0.4 | 1.5 | 1.6 | 1.4 | 0.3 | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 18.4 | 18.4 | 43.8 | 48.0 | 38.8 | 29.7 | 12.5 |
| Operating Income | (31.0) | (31.0) | (96.3) | (67.1) | (56.3) | (43.6) | (22.2) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 1.1 | 1.1 | 3.0 | 4.5 | 1.0 | 0.1 | 0.1 |
| Other Non-Operating Income / Expenses | 2.1 | 2.1 | 3.0 | 4.5 | 1.0 | 0.1 | 0.1 |
| Asset Writedown | — | — | 1.9 | 1.6 | — | — | — |
| EBT, Incl. Unusual Items | (28.9) | (28.9) | (93.4) | (62.6) | (55.3) | (43.5) | — |
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (28.9) | (28.9) | (93.4) | (62.7) | (55.3) | (43.5) | (22.1) |
| Per Share | |||||||
| Basic EPS | — | (18.62) | (1.43) | (1.26) | (1.83) | (3.35) | — |
| Diluted EPS | — | (18.62) | (1.43) | (1.26) | (1.83) | (3.35) | — |
| Basic Weighted Avg Shares | — | 1.6 | 65.1 | 49.8 | 30.2 | 13.0 | — |
| Diluted Weighted Avg Shares | — | 1.6 | 65.1 | 49.8 | 30.2 | 13.0 | — |
| Supplemental | |||||||
| EBIT | (31.0) | (31.0) | (96.3) | (67.1) | (56.3) | (43.6) | (22.2) |
| Effective Tax Rate | -0.0% | — | — | -0.1% | -0.0% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.